静脉化疗联合肝动脉化疗栓塞治疗胃癌伴肝转移

Intravenous chemotherapy in combination with TACE for the treatment of hepatic metastasis of gastric cancer

目的 评价静脉化疗联合肝动脉化疗栓塞治疗胃癌伴肝转移的有效性和安全性.方法 将60例胃癌伴肝转移患者分成2组：试验组30例,经肝动脉化疗栓塞治疗后行静脉化疗,化疗方案：多西他赛60 mg/m^2静脉滴注,第1天;奥沙利铂80 mg/m^2静脉滴注,第1天;5-氟尿嘧啶500 mg/m^2静脉滴注,第1～5天;对照组30例,按上述方案行静脉化疗.4周为1个周期,对所有病例化疗2～6个周期后评价疗效和毒副反应.结果 试验组化疔总有效率53％,卡氏评分提高率70％,对照组分别为37％和40％,差异均有统计学意义（均P＜0.05）;试验组中位总生存时间为13个月,对照组为8个月,差异有统计学意义（P＜0.05）.试验组的毒副反应无明显增加.结论 静脉化疗联合肝动脉化疗栓塞治疗胃癌伴肝转移较单纯静脉化疗疗效明显增加,毒副反应轻且易于控制.

Objective To evaluate efficacy and safety of intravenous chemotherapy combined with TACE in the treatment of gastric cancer with hepatic metastasis.Methods In this study 60 gastric cancer patients with hepatic metastasis were divided into two groups randomly,the trial group （30 cases） took intravenous chemotherapy consisted of docetaxel 60 mg/m^2 intravenous drip d1,oxaliplatin 80 mg/m^2 intravenous drip d1 followed by 5-fiuorouracil 500 mg/m^2 intravenous drip d1-5 after TACE.The control group （30 cases） took the same chemotherapy protocol and one treatment cycle covering 4 weeks.Results The overall response rate in trial group was 53% and the increase rate of Karnofsky was 70% while that was 37% and 40% respectively in the control group （P 〈 0.05）.The median overall survival of trial group was 13 months and which was 8 months in the control group （P 〈 0.05）,meanwhile the toxicities and side reactions of trial group didn＇t increase notably.Conclusions Intravenous chemotherapy combined with TACE is safe and more effective in the treatment of gastric cancer with hepatic metastasis.